Key result
Peripheral blood mitochondrial dysfunction and circulating mtDNA emerge as noninvasive biomarkers for cardiovascular disease.
Why the study?
Understanding the involvement of PBMCs and platelet mitochondrial function, ROS production, and circulating mtDNA release in cardiovascular diseases is valuable given CVD's systemic nature.
Answers are grounded in this paper and cite their sources.
Evaluating mitochondrial function and oxidative stress in circulating blood cells offers a promising noninvasive approach to assess disease severity and prognosis in cardiovascular diseases.
Cardiovascular diseases (CVDs) are devastating disorders and the leading cause of mortality worldwide. The pathophysiology of cardiovascular diseases is complex and multifactorial and, in the past years, mitochondrial dysfunction and excessive production of reactive oxygen species (ROS) have gained growing attention. Indeed, CVDs can be considered as a systemic alteration, and understanding the eventual implication of circulating blood cells peripheral blood mononuclear cells (PBMCs) and or platelets, and particularly their mitochondrial function, ROS production, and mitochondrial DNA (mtDNA) releases in patients with cardiac impairments, appears worthwhile. Interestingly, reports consistently demonstrate a reduced mitochondrial respiratory chain oxidative capacity related to the degree of CVD severity and to an increased ROS production by PBMCs. Further, circulating mtDNA level was generally modified in such patients. These data are critical steps in term of cardiac disease comprehension and further studies are warranted to challenge the possible adjunct of PBMCs' and platelets' mitochondrial dysfunction, oxidative stress, and circulating mtDNA as biomarkers of CVD diagnosis and prognosis. This new approach might also allow further interesting therapeutic developments.
No takes yet. Share an insight, caveat, or question.
Alfatni et al. (2020) conducted a review in Cardiovascular diseases. Mitochondrial dysfunction, oxidative stress, and circulating mtDNA in PBMCs and platelets was evaluated. Mitochondrial dysfunction, increased ROS, and altered circulating mtDNA in peripheral blood mononuclear cells and platelets show potential as noninvasive biomarkers for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: